| Name | Diaceutics |
|---|---|
| Epic | DXRX |
| Isin | GB00BJQTGV64 |
| Index | MID300 |
| Industry | Medical Equipment and Services |
| Latest share price | 133.59p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £113.12 | Debt ratio | n/a |
| Shares in issue | 84.68 | Debt-to-equity ratio | n/a |
| P/E ratio | 87.8 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 1.96 |
| Dividend cover | n/a | EPS growth | 28 |
| Earning per share | 0.86 | 52-week high / low | 83.50p / 134.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Diaceutics |
|---|---|
| Address | First Floor, Building Two, Dataworks at Kings Hall Health and Wellbeing Park, Belfast, County Antrim, United Kingdom, BT9 6GW |
| Telephone | |
| Website | http://www.diaceutics.com |
| Director | Position |
|---|---|
| Mr Ryan Gerard Keeling | CEO |
| Mr Nick Roberts | CFO |
| Mr Graham Paterson | Non-Executive Director |
| Mr Peter Keeling | Executive Director |
| Mr Deborah Davis | Non-Executive Chairman |
| Mr Michael Dennis Wort | Independent Non-Executive Director |
| Mr Richard Charles Hindson | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 15.22 | 12.82 | 9.36 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 17.36 | 14.95 | 9.9 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 11.06 | 10.39 | 6.11 |
| Cash and equivalents | 19.84 | 19.68 | 25.25 |
| Other current assets and asset held for resale | n/a | n/a | 2.26 |
| Total of all assets | 48.26 | 45.01 | 43.52 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 3.75 | 2.63 | 2.91 |
| Long term liabilities | 1.99 | 1.73 | 0.37 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 5.74 | 4.36 | 3.28 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 42.51 | 40.65 | 40.24 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 0.17 | 0.17 | 0.17 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 5.34 | 4.08 | 3.19 |
| Share premium account | 37.13 | 36.86 | 36.86 |
| Total equity | 42.51 | 40.65 | 40.24 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 0.57 | 0.55 | -0.66 |
| Pre-tax profit | 0.56 | 0.46 | -0.68 |